doi: 10.1038/clpt.1989.109.
Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings
Affiliations
- PMID: 2743709
- DOI: 10.1038/clpt.1989.109
Item in Clipboard
Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings
Clin Pharmacol Ther.
1989 Jul.
Abstract
The pharmacokinetics of a single oral dose of 6 mg perphenazine was studied in a group of six slow and six rapid hydroxylators of debrisoquin. Peak serum concentrations of perphenazine were significantly higher in slow hydroxylators than they were in rapid hydroxylators (2.4 +/- 0.6 versus 0.7 +/- 0.3 nmol/L, p less than 0.001). The AUC(0-12) was also higher in slow hydroxylators than it was in rapid hydroxylators (18.5 +/- 6.2 versus 4.5 +/- 2.5 nmol.L-1.hr, p less than 0.001). The data suggest that the disposition of the antipsychotic drug perphenazine covaries with polymorphic debrisoquin hydroxylation.
Similar articles
-
Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators.Clin Pharmacol Ther. 1987 Sep;42(3):278-82. doi: 10.1038/clpt.1987.147. Clin Pharmacol Ther. 1987. PMID: 3621781
-
Polymorphic debrisoquin hydroxylation in 757 Swedish subjects.Clin Pharmacol Ther. 1988 Oct;44(4):431-5. doi: 10.1038/clpt.1988.176. Clin Pharmacol Ther. 1988. PMID: 3168394
-
Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype.Clin Pharmacol Ther. 1987 Mar;41(3):314-9. doi: 10.1038/clpt.1987.33. Clin Pharmacol Ther. 1987. PMID: 3816019
-
Disposition of the neuroleptics perphenazine, zuclopenthixol, and haloperidol cosegregates with polymorphic debrisoquine hydroxylation.Psychopharmacol Ser. 1993;10:230-7. doi: 10.1007/978-3-642-78010-3_21. Psychopharmacol Ser. 1993. PMID: 8103225 Review. No abstract available.
-
Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators.Psychopharmacol Ser. 1989;7:201-5. doi: 10.1007/978-3-642-74430-3_21. Psychopharmacol Ser. 1989. PMID: 2687858 Review. No abstract available.
Cited by
-
Pharmacokinetic optimisation of the treatment of psychosis.Clin Pharmacokinet. 1993 Sep;25(3):217-36. doi: 10.2165/00003088-199325030-00005. Clin Pharmacokinet. 1993. PMID: 7900948 Review.
-
Pharmacokinetics of chlorpromazine and key metabolites.Eur J Clin Pharmacol. 1993;45(6):563-9. doi: 10.1007/BF00315316. Eur J Clin Pharmacol. 1993. PMID: 8157044
-
Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms.Br J Clin Pharmacol. 1994 Jan;37(1):71-4. doi: 10.1111/j.1365-2125.1994.tb04242.x. Br J Clin Pharmacol. 1994. PMID: 8148222 Free PMC article.
-
Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping.J Psychiatry Neurosci. 1994 Jan;19(1):30-44. J Psychiatry Neurosci. 1994. PMID: 8148364 Free PMC article. Review.
-
Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs.Cell Mol Neurobiol. 1999 Aug;19(4):491-510. doi: 10.1023/a:1006938908284. Cell Mol Neurobiol. 1999. PMID: 10379422 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
